Eurofins Scientific has completed the acquisition of 100% of SYNLAB’s clinical diagnostics operations in Spain. The transaction, initially agreed upon in October 2024, was finalized on March 31, 2025. This strategic carve-out allows SYNLAB to optimize its portfolio by exiting the Spanish market to focus on regions with higher strategic impact. For Eurofins, the acquisition is transformative, merging SYNLAB’s assets with its existing Eurofins Megalab network to become the undisputed leader in clinical diagnostics in Spain. The combined entity now possesses a workforce of over 2,000 employees and the capacity to serve more than 10 million patients annually, processing over 100 million tests. The strategic rationale centers on total geographic coverage of Spain and enhanced capabilities in specialized testing such as genetics. The deal was integrated without significant restructuring due to the complementary nature of the laboratory footprints.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, a stable level compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.